
Telo Genomics Corp. — Investor Relations & Filings
Telo Genomics Corp. is a molecular diagnostics company specializing in developing predictive and prognostic solutions utilizing its proprietary telomere-based platform. The core technology, TeloView®, quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres. This platform is designed to provide actionable information regarding disease aggressiveness and potential response to treatment, helping to tailor therapeutic approaches. Applications focus primarily on multiple cancers (oncology) and neurodegenerative diseases (CNS). The company is pioneering the most comprehensive telomere platform in the industry to address unmet market needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-04-14 | English | |
| News release - English.pdf | 2026-04-14 | English | |
| News release - English.pdf | 2026-03-31 | English | |
| News release - English.pdf | 2026-03-31 | English | |
| News release - English.pdf | 2026-02-19 | English | |
| News release - English.pdf | 2026-02-19 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
6 filings
| |||||
| 34503719 | News release - English.pdf | 2026-04-14 | English | ||
| 34486611 | News release - English.pdf | 2026-04-14 | English | ||
| 33122493 | News release - English.pdf | 2026-03-31 | English | ||
| 33121244 | News release - English.pdf | 2026-03-31 | English | ||
| 32100181 | News release - English.pdf | 2026-02-19 | English | ||
| 32080654 | News release - English.pdf | 2026-02-19 | English | ||
|
2025
9 filings
| |||||
| 32374289 | News release - English.pdf | 2025-12-18 | English | ||
| 32359857 | 52-109FV2 - Certification of interim filings - CEO (E).pdf | 2025-11-25 | English | ||
| 32359855 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2025-11-25 | English | ||
| 32359859 | Interim MD&A - English.pdf | 2025-11-25 | English | ||
| 32359860 | Interim financial statements/report – English.pdf | 2025-11-25 | English | ||
| 32343329 | News release - English.pdf | 2025-10-09 | English | ||
| 32332566 | Notice of the meeting and record date - English.pdf | 2025-10-06 | English | ||
| 32322762 | News release - English.pdf | 2025-09-19 | English | ||
| 32313075 | News release - English.pdf | 2025-09-08 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genprex, Inc.
Clinical-stage gene therapy company developing therapies fo…
|
GNPX | US | Professional, scientific and te… |
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
Telo Genomics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/46928/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=46928 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=46928 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=46928 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 46928}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Telo Genomics Corp. (id: 46928)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.